Recent scientific studies underscore the potential of psilocin to drive transformative neuroprotective effects by promoting neuroplasticity, reducing inflammation, and modulating microglial function,
These findings open avenues for research into ALS and other neurodegenerative diseases, where overlapping mechanisms like oxidative stress and neuronal damage are central to disease progression.
At Haim Pharma, we’re leveraging these insights to develop stable, disease-specific psilocin formulations that aim to redefine treatment strategies for neurodegenerative conditions.
Note: This post is for informational purposes only and does not constitute medical advice.